Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Editas Medicine, Inc. Common Stock (EDIT)

Biological Products, (no Disgnostic Substances)

https://www.editasmedicine.com

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

11 HURLEY ST.
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/03/2016

Market Cap

329,080,836

Shares Outstanding

81,670,000

Weighted SO

81,673,688

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

BEAM --.--%

CRSP --.--%

CRBU --.--%

VERV --.--%

NTLA --.--%

PRME --.--%

VRTX --.--%

DNA --.--%

ALLO --.--%

Beta

2.0020

Last Div

0.0000

Range

3.71-11.69

Chg

-0.0100

Avg Vol

2027143

Mkt Cap

329080836

Exch

NASDAQ

Country

US

Phone

617 401 9000

DCF Diff

9.0789

DCF

0.0011

Div Yield

0.0000

P/S

4.9092

EV Multiple

-1.4900

P/FV

1.4155

Div Yield %

0.0000

P/E

-1.6977

PEG

-0.0645

Payout

0.0000

Current Ratio

3.8537

Quick Ratio

3.8537

Cash Ratio

0.8672

DSO

1.3286

DIO

0.0001

Op Cycle

1.3287

DPO

865.1549

CCC

-863.8263

Gross Margin

0.9133

Op Margin

-3.1011

Pretax Margin

-2.8859

Net Margin

-2.8859

Eff Tax Rate

-0.0456

ROA

-0.5027

ROE

-0.6261

ROCE

-0.6695

NI/EBT

1.0000

EBT/EBIT

0.9306

EBIT/Rev

-3.1011

Debt Ratio

0.1006

D/E

0.1668

LT Debt/Cap

0.0812

Total Debt/Cap

0.1430

Int Coverage

-59.9236

CF/Debt

-4.2543

Equity Multi

1.6586

Rec Turnover

274.7254

Pay Turnover

0.4219

Inv Turnover

999999.9999

FA Turnover

1.3116

Asset Turnover

0.1742

OCF/Share

-2.0001

FCF/Share

-2.0841

Cash/Share

3.3910

OCF/Sales

-2.4560

FCF/OCF

1.0420

CF Coverage

-4.2543

ST Coverage

-9.0537

CapEx Coverage

-23.8219

Div&CapEx Cov

-23.8219

P/BV

1.4155

P/B

1.4155

P/S

4.9092

P/E

-1.6977

P/FCF

-1.9183

P/OCF

-1.9949

P/CF

-1.9949

PEG

-0.0645

P/S

4.9092

EV Multiple

-1.4900

P/FV

1.4155

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 06:01 Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 15, 05:19 Down 88%, Could Editas Medicine Be a Good Investment Now? The Motley Fool Jan 08, 07:45 Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals MarketWatch Dec 13, 12:03 Vertex's stock heads for all-time high as non-opioid painkiller shows promise MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 08, 12:03 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment The Motley Fool Dec 04, 08:30 You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. The Motley Fool Nov 20, 05:36 2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street GlobeNewswire Inc. Nov 03, 07:00 Editas Medicine Announces Third Quarter 2023 Results and Business Updates GlobeNewswire Inc. Nov 02, 09:12 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar The Motley Fool Oct 30, 08:30 Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient Investing.com Oct 29, 09:46 Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week Investing.com Oct 29, 09:46 Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week

Revenue Product Segmentation